New business is being written on visibly better terms than the company's own recent norm, and the mix shift has just beg
The model's full reasoning — Q1 2018 call → NOWe need answer YES or NO based on transcript. Need determine if management indicates economic terms of newest business have stepped up meaningfully above company's own recent norm, and improvement only begun to flow into reported results because most business still older terms. We need parse transcript. The question is about "economic terms of company's newest business — prices, rates, fees, spreads, contract sizes, durations, profitability at which most recent deals, orders, contracts, renewals, transactions are being struck" have stepped up meaningfully above company's own recent norm, and improvement only begun to flow into reported results. In transcript, management discusses revenue growth, consumables growth, NovaSeq, microarray, collaborations. But do they indicate that new business terms (pricing, contract sizes, profitability) have improved vs own recent norm and only begun to flow? They mention "milestone payments associated with recently announced oncology collaborations" included in guidance, but not yet recognized in Q1. They mention "pharma collaborations" will have revenue in future, and "we haven't recognized any milestones or contributions from them. We will going forward." But is that about economic terms of new business stepping up? They are new collaborations with BMS and Loxo, but no details on economics. They say "These are multiyear collaborations. We’re kicking them off now. They certainly have milestones that happen over the course of the next couple of years and that the way we’ve restructured, there’s some revenue upfront and some tied to achievement of milestones." That suggests new deals have revenue structure, but not necessarily "meaningfully above recent norm" in terms of pricing/profitability. Also they mention "incremental R&D and commercial projects" and "higher revenue projection" but not terms.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| CRBG | Corebridge Financial, Inc. | Q4 2022 | 2023-02-22 | B |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| MTB | M&T Bank Corporation | Q2 2022 | 2022-07-20 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| GNK | Genco Shipping & Trading Limited | Q2 2021 | 2021-08-07 | A |
| ESS | Essex Property Trust, Inc. | Q2 2018 | 2018-08-03 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
CRL · Q2 2022 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management's comments on Safety Assessment pricing and backlog directly address both required elements: they describe current bookings and backlog at "escalating prices" and "meaningful price increases" that are already achieved on real transactions (not targets or future expectations), while noting that the reported Q2 results are still dominated by older 2022 terms and that the stronger pricing is accelerating into H2 and 2023 bookings.
ESS · Q2 2018 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management describes the loss-to-lease metric rising to 3.
CTO · Q2 2023 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...